Genus Capital Management Inc. Has $2.09 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Genus Capital Management Inc. trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 36.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,255 shares of the biopharmaceutical company’s stock after selling 3,005 shares during the period. Genus Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,090,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Mediolanum International Funds Ltd acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter worth about $11,389,000. iA Global Asset Management Inc. increased its position in Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after purchasing an additional 16,133 shares during the last quarter. Perpetual Ltd acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $2,004,000. Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after purchasing an additional 268,313 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its position in Alnylam Pharmaceuticals by 24.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 118,964 shares of the biopharmaceutical company’s stock worth $54,248,000 after purchasing an additional 23,168 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the sale, the executive vice president owned 21,860 shares in the company, valued at $6,989,297.80. This represents a 7.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Yvonne Greenstreet sold 6,799 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the sale, the chief executive officer owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. The trade was a 6.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,255 shares of company stock worth $6,930,337 in the last 90 days. Insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research reports. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Barclays initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 target price on the stock. Wall Street Zen raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $297.45 on Monday. The company has a market cap of $39.71 billion, a PE ratio of 81.27 and a beta of 0.31. The stock has a 50-day moving average of $311.16 and a 200-day moving average of $358.96. Alnylam Pharmaceuticals, Inc. has a 52-week low of $284.19 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm’s revenue was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.44) EPS. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.